Narcolepsy

Ahmed S. BaHammam is a tenured Professor of Pulmonary and Sleep Medicine at King Saud University, Riyadh, Saudi Arabia. He has published over 450 peer-reviewed articles and book chapters, and authored or edited seven books in the fields of sleep medicine and respiratory disorders. Professor BaHammam is editor-in-chief of Nature and Science of Sleep and serves on the editorial board of several sleep medicine journals. He is the President-Elect of the Asian Society of Sleep Medicine. His research spans topics such as narcolepsy, hypersomnia, obesity hypoventilation syndrome, and the effects of intermittent fasting and mealtime on sleep and circadian rhythms. With more than three decades of dedicated experience in sleep medicine, Professor BaHammam has made lasting contributions to the understanding, diagnosis, and management of narcolepsy and other central hypersomnolence disorders. He is has received the King Saud University Lifetime Achievement Award for his contributions to sleep medicine research. Professor BaHammam also holds leadership roles as Executive Director of Academic Affairs at King Saud University Medical City and Director of both the Prince Naif Health Research Center and the University Sleep Research Center Dr. Amir Sharafkhaneh is a Professor of Medicine (tenured) at Baylor College of Medicine and a leading authority in sleep medicine. He completed his medical degree at Tehran University of Medical Sciences, followed by an internal medicine residency at Long Island College Hospital and a fellowship in Pulmonary, Critical Care, and Sleep Medicine at Baylor College of Medicine, where he also earned a PhD in medical research. With over 25 years of clinical and academic experience, Dr. Sharafkhaneh has authored numerous peer-reviewed publications and book chapters in the fields of pulmonary and sleep medicine. He founded the first accredited sleep medicine fellowship program in Texas and has since trained more than 100 sleep specialists. His work has been supported by multiple federal grants, including initiatives to develop telemedicine programs that expand access to sleep care in underserved areas. Dr. Sharafkhaneh currently co- chairs the VA clinical practice guideline committees for obstructive sleep apnea, insomnia, asthma, and COPD. His research team applies artificial intelligence and advanced data analytics to large-scale electronic health record data to advance the understanding and treatment of sleep and respiratory disorders. He also co-leads .the AI Interest Group of the World Sleep Society S.R. Pandi-Perumal, MSc., is the President and Chief Executive Officer of Somnogen Canada Inc., a Canadian corporation. Pandi is popular among the sleep community. He is a world- acclaimed sleep researcher and has authored over 300 publications and has edited over 25 high-profile academic volumes dealing with various sleep-related topics. His name is also on the list of the top 2% of scientists in the world, compiled by Stanford University, Elsevier, and SciTech Strategies. Drawn to the benefits and significance of the sleep cycle, his personal and professional careers have been involved in advocating/achieving a good night’s slumber. Further details about the editor can be viewed at https:// pandi-perumal.blogspot.com; https://scholar.google.com/citations?hl=en&user=MO90ZXkAAAAJ

• List of contributorsAbout the editorsForewordPrefaceAcknowledgmentsPart I Pathophysiology and neurobiologyCHAPTER 1: Understanding sleep in narcolepsy: sleep physiology, neurobiology, and cognitive impairment mechanismsSyed Shahid Habib1.1 Introduction1.2 Sleep physiology1.3 Normal sleep architecture1.4 Sleep stages and their transitions1.4.1 N1 (Stage 1) sleep1.4.2 N2 (Stage 2) sleep1.4.3 N3 (Stage 3) deepest nonrapid eye movement or slow–wave sleep1.5 Rapid eye movement sleep1.6 Comparing sleep patterns of normal individuals with patients with narcolepsy1.7 Brain networks regulating sleep and wakefulness1.7.1 The concept of “flip–flop” switch1.7.2 Sleep paralysis and cataplexy1.8 Brain neurotransmitters in normal sleep and narcolepsy1.8.1 Memory impairment and cognitive deficits in individuals with narcolepsy1.9 Impact of narcolepsy on cognitive function1.10 ConclusionReferencesCHAPTER 2: Pathophysiology of narcolepsy: genetics and immune systemShahrad Taheri2.1 Introduction2.2 Human leukocyte antigen genes and narcolepsy2.3 Narcolepsy and nonhuman leukocyte antigen immune genes2.4 Narcolepsy and environmental factors2.5 Narcolepsy and humoral immunity2.6 SummaryReferencesCHAPTER 3: Neurotransmitters, genetics, and animal models in narcolepsy: a comprehensive overviewNada F. AlAhmady and Fadwa M. Alkhulaifi3.1 The role of neurotransmitters in narcolepsy: a focus on hypocretin/orexin signaling pathways3.2 The role of immunological and hormonal pathways in narcolepsy3.2.1 The immune basis of narcolepsy3.3 Genetic underpinnings of narcolepsy3.4 The role of animal models in understanding narcolepsy3.5 Common animal models in narcolepsy research3.5.1 Canine narcolepsy3.5.2 Rodent narcolepsy3.5.3 Transgenic models3.5.4 Zebrafish narcolepsy3.6 Implications for treatment and future directionsReferencesCHAPTER 4: The gut–brain axis in narcolepsy: emerging research on microbiota, diet, and sleepFulong Xiao4.1 Introduction4.2 The gut microbiota and sleep disorders4.3 Trends in research about gut microbiota and narcolepsy4.4 ConclusionReferencesPart II Clinical aspectsCHAPTER 5: Types of narcolepsy and their symptoms: differential diagnosis and misdiagnosisRenata Riha5.1 Types of narcolepsies5.1.1 Type 1 narcolepsy5.1.2 Type 2 narcolepsy5.2 Controversies in the diagnosis of type 1 and type 2 narcolepsy5.3 Phenotyping narcolepsy5.4 ConclusionReferencesCHAPTER 6: Delayed diagnosis of narcolepsy: causes and implicationsAbdul Rouf Pirzada and Ahmed S. BaHammam6.1 Introduction6.2 Epidemiological insights into diagnostic delays in narcolepsy6.2.1 Global perspective on diagnostic delay6.2.2 Improvement in diagnostic delay in recent data6.2.3 Access to healthcare services and diagnostic delay6.3 Potential predictors of delayed diagnosis6.3.1 Age6.3.2 Cataplexy6.3.3 Gender6.4 Symptoms overlap with other disorders and prior misdiagnoses of patients with narcolepsy6.4.1 Diagnostic delays and misdiagnosis trends6.4.2 Comparative studies and misdiagnosis rates6.4.3 Comorbidity and symptom complexity6.4.4 Sleep disorders and narcolepsy overlap6.4.5 Diagnostic challenges in pediatric narcolepsy6.4.6 Logistical and diagnostic limitations6.5 Diagnostic delay and clinical implications6.5.1 Clinical and personal consequences of delayed diagnosis6.5.2 Educational challenges6.5.3 Economic and societal impacts6.6 ConclusionReferencesChapter 7: Diagnostic tools for narcolepsy: sleep studies, multiple sleep latency test, and moreAhmed S. BaHammam7.1 Introduction7.2 Overview of American Academy of Sleep Medicine diagnostic criteria for narcolepsy7.2.1 Narcolepsy type 17.2.2 Narcolepsy type 27.2.3 Updates in the 2024 pediatric guidelines include7.3 Emerging roles of CSF hypocretin-1 measurement in narcolepsy diagnosis7.4 Polysomnography7.4.1 Role of polysomnography in narcolepsy diagnosis7.4.2 Typical polysomnography findings in narcolepsy7.4.3 Specific rapid eye movement sleep changes in narcolepsy7.4.4 Limitations of polysomnography alone for diagnosis7.5 Multiple sleep latency test7.5.1 Purpose and procedure of multiple sleep latency test7.5.2 Diagnostic criteria for narcolepsy based on multiple sleep latency test results7.5.3 Pediatric considerations7.5.4 Preparation for the multiple sleep latency test7.5.5 Factors affecting multiple sleep latency test reliability7.6 Daytime continuous polysomnography7.7 Actigraphy7.7.1 Limitations of actigraphy for narcolepsy diagnosis7.8 Screening scales for narcolepsy7.8.1 Ullanlinna Narcolepsy Scale7.8.2 Swiss Narcolepsy Scale7.8.3 Epworth Sleepiness Scale7.8.4 Narcolepsy Severity Scale7.8.5 The Pediatric Hypersomnolence Survey7.8.6 Challenges and opportunities in the use of Narcolepsy Screening Scales7.9 Emerging technologies and artificial intelligence7.9.1 Wearables7.9.2 Pupillometry as a potential biomarker for sleepiness7.9.3 Home sleep testing for narcolepsy diagnosis: current limitations7.9.4 Machine learning in narcolepsy diagnosis7.9.5 Utilizing AI in phenotyping narcolepsy and hypersomnolence disorders7.10 Diagnostic approach7.11 ConclusionReferencesChapter 8: Narcolepsy in children and adolescents: diagnosis, management, and challengesBinal Kancherla, Sonal Malhotra, Marlene Typaldos, Aleena Wasim, and Yousaf Khan8.1 Medical history8.2 Physical exam8.3 Diagnostic testing8.3.1 Sleep diary and actigraphy8.3.2 Overnight polysomnography8.3.3 Multiple sleep latency test8.4 Laboratory testing and imaging8.4.1 Hypocretin testing8.4.2 HLA typing8.4.3 Neuroimaging8.5 Psychological, psychiatric, and social aspects8.6 Differential diagnosis8.7 Management8.7.1 Education8.7.2 Behavioral modification8.7.3 Pharmacological8.7.4 Medications for excessive daytime sleepiness8.7.5 Medications for cataplexy8.7.6 Other medications8.8 Summary of managementChapter 9: Narcolepsy and pregnancy: risks and strategies for managementRosa Peraita-Adrados9.1 Introduction9.2 Narcolepsy in women9.3 Sleep disorders in pregnancy9.4 Narcolepsy in pregnancy9.5 Medication management during pregnancy for narcolepsy patientsReferencesChapter 10: Aging with narcolepsy: understanding the unique challenges for older adultsNatalie Cornay Manalo and Hrayr Attarian10.1 Introduction10.2 Narcolepsy onset after age 3510.2.1 Case 1 (late onset)10.3 Delayed diagnosis10.3.1 Case 2 (delayed diagnosis)10.4 Symptomatic narcolepsy10.4.1 Case 3 (symptomatic narcolepsy)10.5 Implications of narcolepsy in older adults and therapeutic challenges10.5.1 Case 4 (management dilemma with age)10.6 ConclusionReferencesChapter 11: Medical comorbidities of narcolepsyNikita Jambulingam, Nathaniel Yuan, and Alon Y. Avidan11.1 Introduction11.2 Neurological comorbidities11.2.1 Migraines11.2.2 Restless leg syndrome11.2.3 Rapid eye movement sleep behavior disorder11.3 Cardiovascular comorbidities11.3.1 Cardiovascular events and stroke11.3.2 Hypertension11.4 Metabolic comorbidities11.4.1 Obesity11.4.2 Type 2 diabetes11.4.3 Dyslipidemia11.5 Autoimmune disease comorbidities11.5.1 Autoimmune disease and human leukocyte antigen11.5.2 Type 1 diabetes11.5.3 Celiac disease11.5.4 Rheumatoid arthritis11.5.5 System lupus erythematosus11.5.6 Sjögren’s syndrome11.6 Narcolepsy and comorbidities: management perspectives11.6.1 Comorbid neurological treatment considerations11.6.2 Comorbid cardiovascular treatment considerations11.6.3 Comorbid metabolic treatment considerations11.6.4 Comorbid autoimmune disease treatment considerations11.7 ConclusionReferencesChapter 12: Cardiovascular disease risk and comorbidities in narcolepsyAhmed S. BaHammam12.1 Introduction12.2 Epidemiological evidence of increased cardiovascular disease risk12.3 Potential mechanisms linking narcolepsy and cardiovascular disease risk12.3.1 Sleep disruption and autonomic dysfunction12.3.2 The role of hypocretin12.3.3 Metabolic dysfunction12.3.4 Comorbid sleep disorders12.3.5 Inflammation and endothelial dysfunction12.4 Cardiovascular risk assessment and management in narcolepsy12.4.1 Regular cardiovascular risk screening12.4.2 Lifestyle modification12.4.3 Management of comorbidities12.4.4 Consideration of cardiovascular effects of narcolepsy medications12.4.5 Sodium intake and cardiovascular risk in narcolepsy12.5 Future research directions12.6 ConclusionReferencesChapter 13: More than just narcolepsy: the importance of recognizing concurrent sleep disordersAntara Mallampalli, MD13.1 Introduction: comorbid sleep disorders in narcolepsy patients13.2 Prevalence of comorbid sleep disorders in narcolepsy patients: an overview13.3 Sleep-related breathing disorders in narcolepsy patients13.3.1 Pathophysiology of sleep-related breathing disorders in narcolepsy13.3.2 Clinical impact of sleep-related breathing disorders in narcolepsy13.3.3 Summary13.4 Insomnia in narcolepsy patients13.5 Restless leg syndrome and periodic limb movement disorder in narcolepsy patients13.5.1 Pathophysiology of periodic limb movements of sleep and restless leg syndrome in narcolepsy13.5.2 Clinical impact of restless leg syndrome in narcolepsy13.6 REM sleep behavior disorder and other parasomnias in narcolepsy patients13.6.1 Clinical impact of REM sleep behavior disorder in narcolepsy13.7 Conclusion and future research directionsReferencesChapter 14: Narcolepsy and circadian rhythm disorders: diagnosis and managementSona Nevsimalova14.1 Introduction14.2 Circadian and ultradian rhythms in narcolepsy14.3 Hypocretin and circadian system14.4 Circadian aspects of clinical manifestation in narcolepsy14.5 Circadian rhythm disorders and narcolepsy14.6 Recommendations for therapy, management, and future perspectivesReferencesChapter 15: The hidden link between narcolepsy and autonomic dysfunction: a closer lookFang Han15.1 The orexin system and narcolepsy15.2 Orexins in autonomic regulation15.3 Role of orexins in cardiovascular regulation15.4 Narcolepsy and autonomic dysfunction15.5 Cardiovascular dysfunction in narcolepsy15.6 Nondipper profile in narcolepsy with cataplexy15.7 Treatment of narcolepsy on cardiovascular effectsReferencesChapter 16: Narcolepsy and metabolic rate: what do we know?Hamza O. Dhafar and Ahmed S. BaHammam16.1 Introduction16.2 Prevalence of obesity in patients with narcolepsy16.3 Changes in metabolic rate in patients with narcolepsy16.4 Exploring the possible underlying mechanisms of weight gain in narcolepsy16.4.1 The role of orexin in metabolism16.4.2 Orexin and eating behavior16.4.3 Physical activity16.4.4 Genetic factors16.4.5 The role of leptin and ghrelin hormones16.4.6 Metabolomics16.4.7 The role of medications used for narcolepsy16.5 Conclusions and future directionsReferencesChapter 17: Narcolepsy and driving: safety issues and regulationsTha A. Saw and Catherine A. McCall17.1 Introduction17.2 Narcolepsy and drowsy driving17.3 Evaluating drowsy driving risk with narcolepsy17.4 Legal and regulatory issues17.5 Risk mitigation17.5.1 Pharmacologic interventions17.5.2 Nonpharmacologic interventions17.5.3 Patient resources17.6 ConclusionReferencesChapter 18: The natural history of narcolepsy: lessons from longitudinal studiesSalman A. Bahammam and Ahmed S. BaHammam18.1 Introduction18.2 Importance of understanding the natural history and time course of narcolepsy18.2.1 Predicting disease progression18.2.2 Identifying comorbidities18.2.3 Developing targeted therapies and precision medicine18.2.4 Enhancing patient education and support18.3 Longitudinal studies on narcolepsy18.3.1 Age of onset and gender differences18.3.2 Progression of symptoms and clinical findings over time18.3.3 Changes in sleep architecture over time based on sleep study findings18.3.4 Longitudinal changes in orexin levels18.3.5 Impact of narcolepsy on quality of life18.3.6 Long-term data on safety and efficacy of narcolepsy medications18.4 Developing targeted therapies based on natural course18.5 ConclusionReferencesChapter 19: Neuroimaging in narcolepsy: advances in understanding pathophysiology and diagnosisKyung Min Kim, Jun-Sang Sunwoo, and Seung Bong Hong19.1 Introduction19.2 Voxel-based morphometry, volumetry, cortical thickness studies on narcolepsy19.3 Diffusion tensor imaging and narcolepsy19.4 Functional magnetic resonance imaging research on narcolepsy19.5 Magnetic resonance spectroscopy studies on narcolepsy19.6 Single photon emission computed tomography and PET studies in narcolepsy19.7 Future directionsReferencesChapter 20: The distinctive characteristics of REM sleep and dreams in narcolepsySerena Scarpelli and Luigi De Gennaro20.1 Introduction20.2 Rapid eye movement sleep features in narcolepsy20.3 Dream activity in narcolepsy20.4 Neural bases of dream recall20.5 Lucid dreams, nightmares, and insights for treatment20.6 ConclusionsReferencesPart III: Behavioral and psychosocial considerationsChapter 21: The hidden burden of narcolepsy: anxiety and depression among patientsBerit Hjelde Hansen21.1 Introduction21.2 Anxiety disorders21.3 Depressive disorders21.4 Widening the scope—a potential role of neurodevelopmental disorders21.5 Treatment21.6 Importance of screening for anxiety and depression in narcolepsy21.7 SummaryReferencesChapter 22: Understanding psychosis and behavioral abnormalities in narcolepsy patientsCyril Hanin22.1 Introduction22.2 Clinical presentation of psychosis in narcolepsy22.2.1 Psychotic symptoms in narcolepsy22.2.2 Group 1: hallucinations in typical narcolepsy22.2.3 Group 2: narcolepsy with atypical psychotic-like symptoms22.2.4 Group 3: challenges in diagnosing narcolepsy in schizophrenia patients22.3 Impulsivity, emotional dysregulation, and social behavior in narcolepsy22.3.1 Impulsivity in narcolepsy22.3.2 Emotional dysregulation22.3.3 Altered social behavior22.4 Pathophysiology: linking narcolepsy and psychosis22.4.1 REM-sleep intrusion and psychotic-like symptoms22.4.2 Autoimmune and genetic mechanisms22.4.3 Hypocretin system implications22.4.4 Early-onset narcolepsy and schizophrenia: neurodevelopmental implications22.4.5 Medication-induced psychosis in narcolepsy patients with or without comorbid psychotic disorder22.4.6 Classical psychostimulants: methylphenidate and amphetamines22.4.7 Modafinil and armodafinil22.4.8 Sodium oxybate (gamma hydroxybutyrate)22.4.9 Pitolisant and other emerging treatments22.5 Clinical algorithm and management strategies22.5.1 Initial assessment and categorization22.5.2 Assessing drug-induced psychosis22.6 Prognosis and long-term outcomes in narcolepsy patients with psychotic symptomsAI disclosureReferencesChapter 23: Narcolepsy and cognitive impairment: causes and managementMeteb H. Alenazi23.1 Introduction23.2 Cognitive impairment in narcolepsy23.2.1 Attention23.2.2 Memory23.2.3 Executive functions and higher cognitive functions23.3 Clinical pictures of excessive daytime sleepiness and cognitive impairment23.3.1 Hypersomnolence related to major depressive disorder with atypical features23.4 ConclusionAI disclosureReferencesChapter 24: Narcolepsy and relationships: navigating intimacy, family, and social lifeAnne Marie Morse24.1 Introduction24.1.1 Early childhood and adolescence24.1.2 Adulthood24.2 Optimizing outcomes24.2.1 ConclusionReferencesChapter 25: Narcolepsy and advocacy: awareness, education, and community buildingAhmed S. BaHammam25.1 Introduction25.2 The importance of narcolepsy advocacy25.3 Raising awareness about narcolepsy25.4 Educating the general public and healthcare providers about narcolepsy25.4.1 Providing resources25.4.2 Presentations and workshops25.4.3 Correcting common myths25.4.4 Importance of educating healthcare professionals25.5 Building community and support25.5.1 Connecting with other patients25.5.2 Providing encouragement and sharing coping strategies25.5.3 Advocating together for research and better treatments25.6 Empowering patients to advocate for themselves25.6.1 Gaining confidence to discuss narcolepsy25.6.2 Communicating needs and challenges effectively25.6.3 Partnering with healthcare providers25.6.4 Understanding rights and accommodations25.7 The impact of narcolepsy advocacy25.8 ConclusionReferencesFurther readingChapter 26: The complexities of medico-legal assessment of disability in narcolepsyFrancesca Ingravallo and Annamaria Govi26.1 The complexities of medico-legal assessment of disability in narcolepsy26.2 The impact of narcolepsy on work and other major life activities26.3 Aspects of functioning in people with narcolepsy identified by the International Classification of Functioning Core Set for Sleep Disorders26.4 The complexity of medical-legal assessment of disability in narcolepsy26.5 The role of sleep providers26.6 ConclusionsReferencesPart IV: Specific managementChapter 27: Current pharmacological treatments for narcolepsyRitwick Agrawal27.1 Nonpharmacological interventions27.1.1 Addressing comorbid disorders27.1.2 Cognitive behavioral therapy and behavioral approaches to excessive daytime sleepiness27.2 Pharmacological management27.2.1 Primary goals of pharmacological management27.2.2 Pretreatment considerations27.2.3 Excessive daytime sleepiness treatment27.2.4 Cataplexy and excessive daytime sleepiness management27.2.5 Other narcolepsy symptoms27.2.6 Adjustment of initial pharmacological intervention27.3 Special populations27.3.1 Children and young people27.3.2 Pregnancy and lactation27.4 ConclusionAI disclosureReferencesChapter 28: Exploring the potential of cognitive behavioral therapy as an adjunct to medication in narcolepsy managementSultan M. Alshahrani28.1 Introduction28.1.1 Cognitive behavioral therapy for narcolepsy28.1.2 Psychotherapy and psychotherapeutic interventions28.1.3 Education and psychoeducation28.1.4 Conclusion28.2 The psychosocial and psychosomatic aspects of narcolepsy28.2.1 Introduction28.2.2 Psychosocial aspects28.2.3 Psychosomatic aspects28.2.4 Summary28.3 How can psychotherapy help cases with narcolepsy28.3.1 Introduction28.3.2 Mechanism of psychotherapy for individuals with narcolepsy28.3.3 Summary28.4 Cognitive behavioral therapy for narcolepsy28.4.1 Introduction28.4.2 Psychological models for narcolepsy28.4.3 How does cognitive behavioral therapy work for narcolepsy28.4.4 Components of cognitive behavioral therapy for narcolepsy28.4.5 Techniques in cognitive behavioral therapy for narcolepsy patients28.5 Diet and physical activity as components of psychotherapy in narcolepsy28.5.1 Introduction28.5.2 Diet applications for narcolepsy28.5.3 Physical activity and exercise applications for narcolepsy28.6 Other psychotherapeutic interventions for narcolepsy28.6.1 Psychoanalysis for narcolepsy28.6.2 Mindfulness-based interventions for narcolepsy28.6.3 Supportive psychotherapy28.6.4 Psychoeducational therapy (psychoeducation)ReferencesChapter 29: Emerging therapies for narcolepsy: immunotherapy, gene therapy, and beyondTodd J. Swick29.1 Genetics and immunology of narcolepsy29.2 Cell/gene therapy for narcolepsy29.3 Orexin agonists29.4 ConclusionsReferencesChapter 30: Exploring the role of biomarkers and epigenetics in narcolepsy: implications for diagnosis and treatmentAhmed S. BaHammam and Amir Sharafkhaneh30.1 Introduction30.2 Current biomarkers for narcolepsy diagnosis30.2.1 Hypocretin-1 levels in cerebrospinal fluid30.2.2 Genetic markers30.2.3 Epigenetic biomarkers30.2.4 Proteomic biomarkers30.2.5 Other potential biomarkers30.3 Epigenetic mechanisms in narcolepsy pathophysiology30.3.1 Epigenetic changes in narcolepsy (histone modifications, DNA methylation)30.3.2 Role of epigenetic alterations in narcolepsy development and progression30.3.3 Integration of epigenetic mechanisms in narcolepsy pathophysiology30.4 Epigenetic signatures as potential diagnostic markers30.4.1 DNA methylation as a diagnostic biomarker30.4.2 Potential for personalized medicine30.5 Epigenetics in developing novel narcolepsy treatments30.5.1 Epigenetic modulation of hypothalamic neuropeptides30.5.2 Immunomodulatory approaches targeting epigenetic changes30.5.3 Personalized therapy based on epigenetic profiling30.6 Proteomics in narcolepsy pathogenesis30.7 Proteomics in narcolepsy diagnosis30.8 Proteomics in narcolepsy therapeutics30.9 Challenges and limitations30.10 Conclusions and future research directionsReferencesChapter 31: Disease control in narcolepsy: use of telehealth and remote patient management technologyJavad Razjouyan, Amir Sharafkhaneh, Antara Mallampalli, Max Hirshkowitz, and Sharam Moghtader31.1 Introduction31.2 Telehealth for diagnosis and management of narcolepsy31.2.1 Diagnosis of narcolepsy31.3 Management of narcolepsy31.3.1 Medication management31.3.2 Narcolepsy multidisciplinary teams31.3.3 Remote patient monitoring31.4 Application of telesleep for management of obstructive sleep apnea co-occurring with narcolepsy31.5 Application of telesleep for management of insomnia co-occurring with narcolepsy31.6 Application of telesleep for management of psychiatric conditions co-occurring with narcolepsy31.6.1 Technical aspects of telemedicineReferencesChapter 32: The future of narcolepsy treatment: what role will artificial intelligence play?Arash Maghsoudi, Amin Ramezani, Javad Razjouyan, and Amir Sharafkhaneh32.1 What is artificial intelligence?32.2 The role of artificial intelligence in narcolepsy research32.2.1 Artificial intelligence-driven analysis of narcolepsy: uncovering genetic markers32.2.2 Machine learning models for predicting narcolepsy progression32.3 Artificial intelligence in the diagnosis and management of narcolepsy32.3.1 Enhancing diagnostic accuracy with artificial intelligence algorithms32.3.2 Personalized medicine: artificial intelligence in developing customized treatment plans32.4 Wearable technology and artificial intelligence monitoring32.4.1 Smart devices and wearables: tracking sleep patterns and daytime sleepiness32.4.2 Real-time monitoring and artificial intelligence: a new paradigm in narcolepsy management32.5 Artificial intelligence and patient support systems32.5.1 Chatbots and virtual assistants: providing round-the-clock support32.5.2 Artificial intelligence-driven platforms for patient education and community building32.6 Ethical considerations and future directions32.6.1 Navigating the ethical landscape of artificial intelligence in healthcare32.6.2 The future of artificial intelligence in narcolepsy treatment: innovations on the horizon32.7 ConclusionFundingReferencesChapter 33: Narcolepsy and chronic pain: implications and managementZheng Liu, Man Min Zhu, and Hao Huang33.1 Introduction33.2 Epidemiology33.3 Pathophysiological mechanisms33.4 Bidirectional relationship between narcolepsy and chronic pain33.5 Narcolepsy and chronic pain management33.6 Future research directionsReferencesChapter 34: Navigating the costs of narcolepsy in managed careShafaq Mansoor, Elli Allen, and Sudha Tallavajhula34.1 Introduction34.2 Economic burden of narcolepsy34.3 Insurance considerations for approval of testing in narcolepsy34.4 Pharmacotherapy considerations34.5 Strategies to help patients navigate the landscape34.6 Patient access to sleep medicine specialists34.6.1 Strategic drug utilization34.7 SummaryReferencesFurther readingIndex